-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 16th Junshi Bio announced that it had signed a Technology Transfer and Cooperation Agreement with Microscopic Biology, which code-named its four drug projects WJ1024/WJ1075 (with the company's final selection 50% of the interest in WJ05129, APL1898, WJ13404 is transferred to the Company, which will obtain exclusive production, commissioned and sales rights for the above-mentioned drugs worldwide.
The main contents of the Agreement are: (i) Technology transfer and cooperative development of the target situation 1, WJ1024/WJ1075 (based on one of the company's final selection), a rapidly metabolic oral broad-spectrum anti-tumor small molecule drug based on the design of co-price inhibitor characteristics, clinically available for a variety of hematomas and solid tumors.
2, WJ05129, an oral small molecule Aurora A inhibitor.
Aorora A inhibitors have a synthetic lethal effect with RB1 gene loss or inergicity and can be used to treat malignant tumors such as small cell lung cancer and triple-yin breast cancer that are missing or infested.
3, APL1898, a targeted small molecule inhibitor that effectively inhibits the insertion of EGFR-exon20 into variation.
preclinical data show that the drug molecule maintains the activity of inhibiting common EGFR mutations such as T790M, but at the same time overcomes the insensitiveity of third-generation EGFR inhibitors to exon20 insertion variants.
4, WJ13404, an effective fourth-generation EGFR inhibitor.
preclinical data show that the drug molecule has good inhibitory activity against the acquisition EGFR variants that are insensitive to third-generation EGFR inhibitors, including Del19/T790M/C797S and L858R/T790M/C797S, and is highly selective for wild EGFR.
(ii) Technology Transfer Micro-Bio transfers 50% interest in the above four drugs (including, but not limited to, research and development technology and related patent applications, continuation of clinical trials, etc.) and exclusive production, commissioned production and sales rights worldwide upon approval to the Company.
(iii) The two sides will jointly promote the preclinical research work of the above-mentioned drugs in accordance with the Agreement, and the Company will be responsible for the application for clinical trials, the follow-up of clinical trials and the application for drug registration and the licensing of market sales, etc. shall be determined by the joint steering committee jointly established by the two parties.
(4) Financial Terms 1, Down Payment Company will pay a down payment of RMB36 million to Microscopic Biology.
2, research and development and sales milestones The company will pay micro-organisms a cumulative milestone of no more than RMB436 million based on the progress of research and development and commercialization.
3, sales of a profit from the commercial sale of each drug, the company will pay micro-organisms the product sales net profit of 50% of the sales of the sales of the sales.
(v) Intellectual Property Rights The intellectual property rights formed in the past, present and future of the above-mentioned drug projects shall be shared between the two parties in proportion to their respective interests after the company has made a down payment to micro-organisms in accordance with the Agreement.
(6) Conditions of entry into force of the Agreement The Agreement shall enter into force from the date on which the parties sign and seal the Agreement and shall cease until the date on which the obligations of the two parties have been fully fulfilled or after the termination by consensus of the parties or on the date of termination as stipulated in this contract.
.